Winston-Salem 6/16/2011 9:57:47 PM
News / Finance

SmallCapReview - Small Cap Stocks On the Move - WTFS, MDMD, NGSX

SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999.

Xinde Technology Company (OTCBB: WTFS) $0.73, Up $0.13. Today announced that following successful tests and market studies, and the granting of technical patent certification and exclusive manufacturing and distribution rights for its breakthrough diesel engine FIRCRI common rail electrically-controlled fuel injection system, the Company is confident the new system -- jointly developed with engineers at Tianjin University -- will end the technical monopoly currently enjoyed in China by foreign manufacturers in this key product category.

Supply Letter of Intent with Weichai Power

Mr. Dianjun Liu, President and Chief Executive Officer of the Company stated, "Our confidence in this very significant 'home grown' product is supported by the supply letter of intent we have concluded with Weichai Power Co., Ltd, one of the main diesel engine manufacturers in the PRC. They are prepared to purchase 200,000 sets of products yearly whenever our new diesel fuel injection system comes to market, which we currently estimate could be in approximately 18 to 24 months. At that time, we expect to be the sole domestic manufacturer of an electrically-controlled diesel fuel injection system that meets and exceeds the new emission standards that will become mandatory in China in 2015. Further, with significantly lower manufacturing costs than current foreign leaders in this market such as Bosch and Denso, we believe our new product will be quite competitive and are seeking additional supply LOA's with other domestic diesel engine manufacturers."

What They Do: Based in China's Shandong Province in the city of Weifang, Xinde Technology Company, with fiscal 2010 revenues of $123 million, competes in three primary product segments, namely (1) fuel injection system products, (2) diesel engine products and (3) generator products.

Mediamind (Nasdaq: MDMD) $22.06, Up $6.12, and DG (Nasdaq: DGIT) Today announced jointly a definitive agreement under which DG will acquire MediaMind in an all-cash transaction. The acquisition creates one of the premier global online and television advertising technology companies.

MediaMind is a unique asset, with tremendous people, products and services in the fast-growing $71 billion global online advertising market1 with a superb international footprint and broad agency relationships. Headquartered in New York, MediaMind has 37 sales and representation offices covering 64 countries. In 2010, MediaMind delivered campaigns for 9,000 brand owners using approximately 3,800 media and creative agencies across 8,200 global web publishers in 64 countries.

Under the terms of the transaction, which has been approved by the boards of directors of both companies, DG will commence a tender offer to purchase all of MediaMind’s outstanding shares for $22.00 per share in cash. The total transaction value is $517 million equity value or $414 million enterprise value, taking into account over $100 million in cash on MediaMind’s balance sheet. The board of directors of MediaMind will recommend that MediaMind shareholders tender their shares in the tender offer. The transaction is expected to be accretive to DG’s non-GAAP EPS in 2012.

What They Do: MediaMind is a leading global provider of digital advertising campaign management solutions to advertising agencies and advertisers.

NeurogesX (Nasdaq: NGSX) $3.24, Up $0.58. Today announced the completion of patient enrollment in its Phase 2 clinical study of NGX-1998, a topical liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN).  NGX-1998 is being developed to provide safety, efficacy and tolerability that is at least comparable to Qutenza® (capsaicin) 8% patch with a shorter treatment time.  A total of 183 patients were enrolled in the Phase 2 study.

The Phase 2 clinical study design included two stages. The first stage was designed to determine the shortest tolerable anesthetic pretreatment regimen. The results of this stage of the study indicated that no topical anesthetic was required to achieve the study's tolerability goal.  The second stage was designed to evaluate two NGX-1998 dose concentrations using the pretreatment regimens determined during stage 1. The objective of the second stage is to select the appropriate concentration of NGX-1998 for further evaluation in a Phase 3 clinical program.

What They Do: NeurogesX is a biopharmaceutical company focused on developing and commercializing novel pain management therapies.


About SmallCapReview

Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit www.SmallCapReview.com. SCR may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our website or within our reports. SCR has been compensated three thousand five hundred dollars by a third party Winning Media for its efforts with regards to Xinde Technology Company.